



Article

Evidence for Complex Formation of the *Bacillus cereus* Haemolysin BL Components in Solution

Franziska Tausch ¹, Richard Dietrich ¹, Kristina Schauer ¹ , Robert Janowski ²,
Dierk Niessing ^{2,3} , Erwin Märflbauer ¹ and Nadja Jessberger ^{1,*}

¹ Department of Veterinary Sciences, Faculty of Veterinary Medicine, Ludwig-Maximilians-Universität München, Schönleutnerstr 8, 85764 Oberschleißheim, Germany; Franziska.Tausch@gmx.de (F.T.); r.dietrich@mh.vetmed.uni-muenchen.de (R.D.); kristina.schauer@mh.vetmed.uni-muenchen.de (K.S.); e.maerflbauer@mh.vetmed.uni-muenchen.de (E.M.)

² Institute of Structural Biology, Helmholtz Zentrum München-German Research Center for Environmental Health, Ingolstädter Landstr. 1, 85764 Neuherberg, Germany; robert.janowski@helmholtz-muenchen.de (R.J.); niessing@helmholtz-muenchen.de (D.N.)

³ Biomedical Center of the Ludwig-Maximilians-Universität München, Department of Cell Biology, 82152 Planegg-Martinsried, Germany

* Correspondence: n.jessberger@mh.vetmed.uni-muenchen.de; Tel.: +49-89-2180-78577; Fax: +49-89-2180-78602

Academic Editor: Alexey S. Ladokhin

Received: 16 August 2017; Accepted: 12 September 2017; Published: 16 September 2017

Abstract: Haemolysin BL is an important virulence factor regarding the diarrheal type of food poisoning caused by *Bacillus cereus*. However, the pathogenic importance of this three-component enterotoxin is difficult to access, as nearly all natural *B. cereus* culture supernatants additionally contain the highly cytotoxic Nhe, the second three-component toxin involved in the aetiology of *B. cereus*-induced food-borne diseases. To better address the toxic properties of the Hbl complex, a system for overexpression and purification of functional, cytotoxic, recombinant (r)Hbl components L₂, L₁ and B from *E. coli* was established and an *nheABC* deletion mutant was constructed from *B. cereus* reference strain F837/76. Furthermore, 35 hybridoma cell lines producing monoclonal antibodies (mAbs) against Hbl L₂, L₁ and B were generated. While mAbs 1H9 and 1D8 neutralized Hbl toxicity and thus, represent important tools for future investigations of the mode-of-action of Hbl on the target cell surface, mAb 1D7, in contrast, even enhanced Hbl toxicity by supporting the binding of Hbl B to the cell surface. By using the specific mAbs in Dot blots, indirect and hybrid sandwich enzyme immuno assays (EIAs), complex formation between Hbl L₁ and B, as well as L₁ and L₂ in solution could be shown for the first time. Surface plasmon resonance experiments with the rHbl components confirmed these results with K_D values of 4.7×10^{-7} M and 1.5×10^{-7} M, respectively. These findings together with the newly created tools lay the foundation for the detailed elucidation of the molecular mode-of-action of the highly complex three-component Hbl toxin.

Keywords: *Bacillus cereus*; complex formation; enterotoxins; haemolysin BL; monoclonal antibodies

1. Introduction

The Gram-positive, facultative anaerobe and rod-shaped bacterium *Bacillus cereus* has become increasingly important as a cause of food poisoning outbreaks. It is ubiquitous in soil, sediments, dust and plants [1]. From there, it can easily be spread to different foods. *B. cereus* is found in an extraordinary variety of food, as for example in milk and dairy products, rice and pasta or spices,

dry foods and vegetables [1–3]. Food poisoning caused by *B. cereus* is mostly moderate and self-limiting, but also severe and even lethal cases have been reported [4–6].

B. cereus causes mainly two types of foodborne diseases, an emetic and a diarrheal form. The first is characterized by nausea and vomiting and is caused by the cyclic dodecadepsipeptide cereulid, which is produced in foods before consumption [7,8]. Three types of enterotoxins are responsible for the diarrheal form. These are produced foremost in the intestine from viable bacteria that, most likely as spores, survived the stomach passage [9]. These enterotoxins are the three component complexes Hbl (haemolysin BL; [10]) and Nhe (non-haemolytic enterotoxin; [11]), and the single protein CytK (cytotoxin K; [4]). CytK has been reported to be haemolytic, cytotoxic, necrotic and is a member of the family of β -barrel pore forming toxins [12,13]. Only very few strains express the highly toxic CytK1 variant and are classified as *Bacillus cytotoxicus* [14].

The more complex Nhe and Hbl toxins consist of three components each, namely NheA, B and C and Hbl L₂, L₁ and B. It has been shown that for both toxins all three components are needed for maximum biological activity [10,15]. Intensive studies have been performed on the mode of action of Nhe. It has been shown that NheB and C, but not NheA can bind to Vero cells. Nhe is a pore forming toxin inducing cell lysis with an optimum molar ratio for maximum toxicity of A:B:C = 10:10:1. Increasing ratios of NheC lead to inhibition of the toxic activity [15,16]. Moreover, a specific binding order, i.e., NheC-B-A, is necessary for Nhe activity [17–19]. The mode-of-action of Nhe was clarified with the help of monoclonal antibodies (mAbs), which hinder the interaction between the single Nhe components and thus, neutralize the toxic activity [18,20]. On the other hand, these specific mAbs were also used to detect complex formation of Nhe components in culture supernatants, such as the interaction between NheB and C [21].

Hbl was originally purified from *B. cereus* strain F837/76 and a binding component (B) as well as two lytic components (L₂ and L₁) were identified [22,23]. Several different ideas about the mode of action of Hbl exist. First, it has been suggested that each component is able to bind individually to erythrocytes and thus, that they assemble into a “membrane attack complex”, then form a transmembrane pore and lyse the cells [24]. Osmotic protection assays showed that Hbl is a pore forming toxin and that pores are smaller than 1.2 nm [24]. On blood agar plates, it was observed that excess of Hbl L₁ or B inhibits haemolytic activity [24,25]. Thus, a certain concentration ratio of the Hbl components might also be required for maximum activity, but this is, in contrast to Nhe, so far unknown. In another approach it was shown that sequential binding in the specific binding order of Hbl B-L₁-L₂ leads to toxic activity in cell viability tests on Chinese hamster ovary cells [19]. As the crystal structure of Hbl B was solved, a high structural similarity to *E. coli* haemolysin E (HlyE; ClyA) was observed despite low sequence homology [26]. Based on this similarity, another model was proposed in which Hbl B alone might be able to oligomerize on the cell surface and form a pore. L₂ and L₁, which are definitely required for toxic activity, might either stabilize B, induce conformational changes to B or even enter the cell [26].

Investigating Hbl activity in natural *B. cereus* culture supernatants is difficult, as all known enteropathogenic strains that bear *hbl* also have the *nhe* operon. The *nhe* genes can be found in all enteropathogenic *B. cereus* strains, the *hbl* genes in about 45%–65% [27–29]. Early studies on Hbl activity were carried out with proteins purified via anion exchange chromatography from *B. cereus* culture supernatants [23,30]. These might have contained trace contaminations and the use of recombinantly expressed and purified Hbl (rHbl) components was recommended [10]. For a long time rHbl components could not be generated, it was even suggested that the individual components might be toxic for *E. coli* [31]. Only in 2013, Sastalla and co-workers were able to overexpress *B. cereus* Nhe and Hbl proteins in a *Bacillus anthracis* expression system [19].

The aim of this study was to create suitable and effective tools by which the complex mode-of-action of Hbl can be investigated. First, functional rHbl components were overexpressed and purified from *E. coli* in an easy, fast and secure (S1) system. Secondly, a deletion mutant from *B. cereus* reference strain F837/76 was constructed lacking the *nhe* operon. Finally, a whole set of highly specific

mAbs against the three Hbl components was generated. Based on these reagents, it could be shown for the first time that Hbl components L₁ and B, as well as L₁ and L₂ form complexes in solution.

2. Results

2.1. Generation of Functional Recombinant Hbl (rHbl) Components and a $\Delta nheABC$ Mutant

To generate functional, recombinant Hbl toxin, an approach based on the Strep-tag[®] purification system (iba lifesciences) was used. rHbl L₂ and B were expressed with an N-terminal, rHbl L₁ with a C-terminal strep-tag. Sequences encoding putative secretion signal peptides were eliminated. Amino acid sequences and predicted molecular weight of the new recombinant proteins are shown in Figure 1A. The proteins were overexpressed in *E. coli* BL21 (DE3) and purified via affinity chromatography. Purification was controlled in Western blots (Figure 1B). Each of the single components was detected by a strep-specific antibody as well as by the Hbl-specific mAbs. rHbl L₂ and L₁ were detected at their predicted molecular weight of 48.7 and 42.4 kDa, while rHbl B appeared slightly bigger in Western blot analyses than its predicted 40.9 kDa. For rHbl L₁, a second band was detected with the L₁- but not with the strep-specific mAb, indicating partial cleavage of the tag.

A $\Delta nheABC$ mutant was constructed from *B. cereus* strain F837/76. The *nhe* operon was replaced by a spectinomycin resistance cassette, which was confirmed by sequencing. The start and stop codon, as well as the first 36 and the last 18 bp of the operon remained. No phenotypical differences could be detected compared to the wild type (Figure 1C). Western blots (Figure 1D) confirmed that no Nhe toxin was produced by the deletion strain.

To determine the toxic activity of the newly generated rHbl components and the $\Delta nheABC$ strain, they were analysed by PI influx tests as well as by WST-1-bioassays. The rHbl components were clearly able to induce pore formation in Vero cells when applied simultaneously (Figure 1E). Fluorescence could be measured after approximately 25 min, while supernatant of strain F837/76, which was used as control, caused almost immediate PI influx. Simultaneously applied rHbl components were also able to kill Vero cells (Figure 1F), although the reciprocal titre (the dilution to get 50% viable cells after 24 h) was significantly lower than that of F837/76 supernatant (250 compared to 700). The $\Delta nheABC$ mutant showed decelerated PI influx compared to the wild type (Figure 1E) as well as a reduced reciprocal cytotoxicity titre (400 compared to 700; Figure 1F). Altogether, these results prove that, in contrary to earlier claims, overexpression and purification of functional rHbl in *E. coli* as well as the deletion of the *nhe* operon in *B. cereus* is indeed possible.




Figure 1. Cont.




Figure 1. Properties of the recombinant Hbl components and the *nheABC* deletion strain. (A) Amino acid sequences of rHbl L₂, L₁ and B. Strep-tags are shown in blue, linker amino acids in orange letters, the predicted secretion signal sequences are underlined and eliminated sequences are highlighted in grey. From these sequences the molecular weight was predicted (http://web.expasy.org/compute_pi/). (B) Detection of the rHbl components in Western blots. The strep-specific StrepMAB-Classic was used for detection (upper blot), as well as the Hbl-specific mAbs 8B12 (L₂) [32], 1E9 (L₁) [29] and 1B8 [29] (lower blot). (C) Growth of *B. cereus* strains F837/76 and F837/76 Δ*nheABC* in LB medium. Medium was inoculated to an OD₆₀₀ of 0.005 and growth at 37 °C was monitored for 24 h. (D) Western blot. NheA, B and C were detected in the supernatant of strain F837/76 using the mAbs 1A8 [20], 2B11 [20] and 3D6 [21], respectively. These proteins were not detected in the supernatant of the *nheABC* deletion mutant. (E) Influx of PI into Vero cells, represented by increasing fluorescence counts. 1.5 pmol/μL rHbl components were either used separately or mixed in a 1:1:1 ratio and applied in 1:40 dilution to the cells, as was supernatant of F837/76 Δ*nheABC*. CGY medium and supernatant of F837/76 were used as controls. (F) Results of a WST-1-bioassay (Vero cells) determining toxic activity of the *nheABC* deletion strain and the rHbl components (1.5 pmol/μL each, separately or mixed in a 1:1:1 ratio). CGY medium and supernatant of F837/76 were used as controls.

2.2. Generation of Monoclonal Antibodies (mAbs) against Hbl

Highly specific mAbs were generated in this study according to established procedures [20,32]. For immunogen preparation, strain MHI 1532 was chosen, as it showed the highest Hbl B titres in indirect EIAs and the highest Hbl L₂ titres in sandwich EIAs of all strains tested in preliminary experiments (data not shown). The immunogen was gained by purification of the culture supernatant via Hbl B-specific IAC with the already established Hbl B-specific mAb 1B8 [29]. Purified Hbl toxin was used for immunization and two booster injections of mice. After cell fusion, 35 hybridoma cell lines secreting Hbl-reactive antibodies could be identified (Table S1). The target antigens of the mAbs were determined in indirect EIAs using rHbl components. Twenty-nine hybridoma cell lines produced Hbl B-specific mAbs, four mAbs were cross-reactive with Hbl B and Hbl L₁, and two mAbs were specific for Hbl L₂. As mice were immunized with a preparation of IAC-purified Hbl B from *B. cereus* culture supernatants (see above), this finding gave a first hint that the single Hbl components form complexes in solution.

With respect to affinity, stability and productivity of the hybridoma cell lines, 1G8 and 12D12 (Hbl B/L₁), 1D8 and 1H9 (Hbl L₂), and 2G4, 1D7, 1D12 and 1C12 (Hbl B) were chosen for mass production and the respective, purified mAbs were used for further experiments.

2.3. The Generated mAbs Show Neutralizing and Enhancing Properties towards Hbl Toxicity

To investigate the neutralizing properties of the generated mAbs against Hbl, antibodies were applied simultaneously with culture supernatants of *B. cereus* strain F837/76 $\Delta nheABC$ in WST-1-bioassays on Vero cells. The reciprocal titre of the untreated supernatant was set to 100% and relative cytotoxicity of all tested samples was compared to that value. mAbs 1H9 and 1D8 (Hbl L₂-specific) clearly reduced the toxic activity of the Hbl-containing *B. cereus* supernatant by approximately 60%, while unexpectedly mAbs 1D7 (Hbl B), 1D12 (Hbl B) and 12D12 (Hbl B/L₁) enhanced it by 256, 101 and 165%, respectively (Figure 2A). Isotype controls as well as all other tested mAbs showed no significant influence on Hbl toxicity. The three mAbs enhancing Hbl toxicity were used in flow cytometric analyses to determine their influence on Hbl B binding to Vero cells. For that, Vero cells were incubated for 1 h with rHbl B (6.5 pmol/mL) and then probed with Alexa Fluor[®] 488-labelled mAb 1G8 (Hbl B/L₁-specific). These settings resulted in approximately 42% fluorescence (FL1)-positive cells (Table 1). Co-incubation of rHbl B and mAbs 1D12 and 12D12 on Vero cells resulted in no and only slightly enhanced number of FL1-positive cells, respectively. However, when rHbl B was co-incubated on Vero cells with the Hbl B-reactive mAb 1D7, nearly all cells were FL1 positive (96.37%) (Table 1 and Figure 2B). Under consecutive incubation conditions, in which Vero cells were first incubated with rHbl B and then, after washing, with mAb 1D7, this effect was not seen. Negative and isotype controls proved the specificity of the reaction (Table 1). Overall, it could be demonstrated that rHbl B binds specifically to Vero cells and that Hbl B-specific mAb 1D7 enhances this binding by a so far unknown mechanism. The variety of enhancing or neutralizing properties indirectly indicates that the generated mAbs recognize different epitopes.




Figure 2. Influence of mAbs on Hbl toxicity. (A) WST-1-Bioassay on Vero cells. Supernatant of F837/76 $\Delta nheABC$ was applied as serial dilution. mAb (10 $\mu\text{g}/\text{well}$) was added to each dilution and incubated with the cells for 24 h. Cytotoxicity titres were determined by addition of WST-1. The reciprocal titre of the untreated *B. cereus* supernatant was set to 100%. (B) Flow cytometry results of Vero cells treated with rHbl B. Cells were incubated for 1 h with either only buffer (black curve), Hbl B-specific mAb 1D7 (red curve), rHbl B (light green filled) or rHbl B + mAb 1D7 (dark green filled). Cell-bound rHbl B was detected by using Alexa Fluor[®] 488-labelled mAb 1G8 (Hbl B-specific).

Table 1. Flow cytometry of Vero cells treated with rHbl B. Vero cells (1×10^6) were incubated for 1 h with rHbl B (6.5 pmol/mL) and simultaneously with mAbs 1D7 (Hbl B-specific), 1D12 (Hbl B-specific) or 12D12 (Hbl B/L₁-specific) (ratio mAb:rHbl B = 1:1). Fluorescence was detected via Hbl B-specific Alexa Fluor[®] 488-labelled mAb 1G8 (FL1, fluorescence at 488 nm).

Sample	FL1-Positive (%)
negative controls:	
-	0.69 ± 0.29
1D7	0.96 ± 0.12
1D12	0.68 ± 0.03
12D12	0.53 ± 0.06
rHbl B and mAbs co-incubated:	
rHbl B	41.95 ± 6.3
rHbl B + 1D7	96.37 ± 4.34
rHbl B + 1D12	43.99 ± 6.42
rHbl B + 12D12	50.81 ± 4.11
rHbl B and mAb 1D7 consecutively:	
rHbl B, 1D7	32.76 ± 24.61
isotype controls:	
rHbl B + IgG1	58.37 ± 7.33
rHbl B + IgG2a	46.36 ± 1.34

2.4. Complex Formation of rHbl Components

The panel of Hbl-specific mAbs with putative different epitope-specificity offered the opportunity to investigate possible interactions between the single rHbl components. For that, Dot blots and enzyme immunoassays were performed. For Dot blot analyses, a dilution series (480–3.75 pmol) of the first rHbl component was applied to a PVDF membrane, which was then incubated with the second rHbl component (30 pmol in PBS). For detection, a specific mAb against the second rHbl component was used. Hereby, specific interactions between rHbl L₁ and B as well as rHbl L₁ and L₂, but not rHbl L₂ and B were demonstrated, whereat the application order of the rHbl components was not important (Figure 3A and Figure S1). A similar composition applied in indirect EIAs confirmed the specific complex formation between rHbl L₁ and B, and rHbl L₁ and L₂ (Figure 3B). These complexes could also be detected in a different approach where rHbl L₁ and B, and rHbl L₁ and L₂ were pre-incubated for 30 min and subsequently detected in highly specific sandwich EIAs (Figure 4A). This variant also allowed the comparison of different ratios of the single rHbl components (Figure 4B). Hbl complexes were detected in all tested variants. In the 1E9-1B8-sandwich EIA, rHbl L₁ + B complexes were less well detected with excess of B. Excess of L₁ had little influence on complex detection compared to the 1:1 ratio. In the 1G8 (Hbl HblB/L₁-1H9 Hbl L₂)-sandwich EIA, rHbl L₁+L₂ complexes were less well detected with excess of L₂. A ratio of L₁:L₂ of 5:1 resulted in the highest absorption values, while further excess (10:1) showed no difference to the 1:1 control. Complex formation between rHbl L₂ and B could be detected neither in indirect nor in sandwich EIAs (data not shown).

Finally, complex formation between rHbl L₁ and L₂ as well as rHbl L₁ and B was confirmed via surface plasmon resonance (SPR). For that, rHbl L₁ was immobilized, and rising concentrations (from 7.8 nM to 2 µM) of rHbl L₂ and B were added. K_D values of 1.5×10^{-7} M and 4.7×10^{-7} M were determined, respectively (Figure 5A,B). When rHbl L₂ was coupled to the sensor chip, only interaction with rHbl L₁ was detected, not with B (data not shown). Interestingly, switching rHbl B and L₂ (B coupled and L₂ used as ligand), resulted in specific interaction of the two proteins, with a, compared to the results obtained in Figure 5A,B, relative low K_D value of 3.4×10^{-6} M (Figure 5C).




Figure 3. Detection of rHbl complex formation. (A) Dot blot. PVDF membranes were coated with rising concentrations (3.75–480 pmol) of different rHbl components. After blocking, the membrane was incubated in PBS with the second component (30 pmol). Proteins were detected using the Hbl B-specific mAb 1B8 [29] and the Hbl L₂-specific mAb 1H9 (this study). Inversion of the protein order showed similar results and negative controls confirmed the specificity of the reaction (see Figure S1). (B) Indirect EIA. The first rHbl component was applied as serial dilution to a microtiter plate. After washing, the second rHbl component was applied in constant concentration (60 pmol/mL). After blocking, Hbl B-specific mAb 1B8 [29] and Hbl L₂-specific mAb 1H9 (this study) were applied, respectively, followed by rabbit-anti-mouse-HRP conjugate for detection. Details on the non-linear regression are shown in Table S2.




Figure 4. Cont.




Figure 4. Detection of rHbl complex formation via sandwich EIAs. (A) Microtiter plates were coated with mAbs 1E9 (Hbl L₁) [29] and 1G8 (Hbl B/L₁) (this study), respectively. rHbl components were pre-mixed (each 1.5 pmol/ μ L in an 1:1 ratio), incubated for 30 min at RT and, after blocking, applied as serial dilution. After washing, the specific conjugates 1B8-HRP (Hbl B) [29] and 1H9-HRP (Hbl L₂) (this study) were used for detection. (B) In an analogous approach, rHbl components were pre-mixed in different concentration ratios (each 1.5 pmol/ μ L, ratios 1:1, 5:1, 10:1, 1:5 and 1:10). Details on the non-linear regression are shown in Table S2.




Figure 5. SPR measurement of the rHbl components. On the left side, a representative sensogram is depicted. Right panels show binding curves fitted to a one-site-binding model with calculated equilibrium dissociation rates (K_D) and errors as standard deviations from three or four independent experiments. (A) rHbl L₁ immobilized on a sensor chip. Concentration series (7.8 nM—yellow, 15.6 nM—magenta, 31.2 nM—red, 62.5 nM—cyan, 125 nM—green, 250 nM—blue and gray, 500 nM—dark yellow, 1 μ M—dark magenta and 2 μ M—dark red) of rHbl L₂ were applied. (B) rHbl L₁ immobilized on a sensor chip. Concentration series (7.8 nM—yellow, 15.6 nM—magenta, 31.2 nM—red, 62.5 nM—cyan, 125 nM—green, 250 nM—blue and gray, 500 nM—dark yellow, 1 μ M—dark magenta and 2 μ M—dark red) of rHbl B were applied. (C) rHbl B immobilized on a sensor chip. Concentration series (31.2 nM—yellow, 62.5 nM—magenta, 125 nM—red, 250 nM—cyan and green, 500 nM—blue, 1 μ M—gray, 2 μ M—dark yellow and 4 μ M—dark magenta) of rHbl L₂ were applied. RU: response units. Details on the non-linear regression are shown in Table S2.

2.5. Complex Formation in Natural *B. cereus* Culture Supernatants

To detect complex formation of Hbl components in natural *B. cereus* supernatants, sandwich EIAs were performed with serial dilutions of F837/76 supernatant (analogously to Figure 4). Hbl L₁-B complexes could be detected (Figure 6A). As only very weak signals were detected in the Hbl L₁-L₂-specific sandwich EIA (Figure 6B), the specific mAbs were switched (anti-L₂ 1H9 as capture and anti-L₁ 1G8 as detection antibody) and clearer signals were determined (Figure 6C). Altogether, with the complex sandwich EIAs, effective tools were developed to prove Hbl complex formation not only within recombinant Hbl components, but also in natural *B. cereus* culture supernatants.




Figure 6. Hbl complex formation in natural *B. cereus* supernatants. In all tests, supernatant of strain F837/76 was applied as serial dilution. **(A)** Sandwich EIA specific for Hbl L₁-B complexes, using mAb 1E9 (Hbl L₁) and the 1B8-HRP conjugate (Hbl B) [29]. **(B)** Sandwich EIA specific for Hbl L₁-L₂ complexes, using mAb 1G8 (Hbl L₁) and the 1H9-HRP conjugate (Hbl L₂) (this study). **(C)** Due to weak results in Figure 6B, the capture and detection mAbs for Hbl L₁ (1G8) and L₂ (1H9) were switched. Details on the non-linear regression are shown in Table S2.

In an independent approach, MHI 1532 supernatant was purified via IAC using the Hbl B-specific mAb 1B8 [29] equivalently to the generation of the immunogen. Single fractions were collected and

tested in sandwich EIAs. Results of three independent approaches are summarized in Table 2. Hbl B and L₁ bound with high capacity to the IAC column, less than 5% of these toxin components were detected in sample flow-through and wash fraction. The detectable proportion of Hbl B and L₁ in the elution fraction averaged at 187% and 180% compared to the MHI 1532 supernatant. The recovery rate of Hbl L₂ in the elution fraction averaged at only 29%, while 51% were detected in the sample flow-through and 20% in the wash fraction. A sandwich EIA against the toxin component NheB was performed to exclude unspecific binding of toxin components to the immunosorbent. Indeed, 97% of NheB were detected in the sample flow-through. As a control, the identical experiment was performed using the Hbl L₂-specific mAb 1H9 coupled to the CnBr-activated sepharose 4B matrix. Ninety percent of Hbl L₂ were retrieved in the elution fraction, whereas only 2% and 1% of Hbl L₁ and B were detected, respectively (Table 2). Corresponding Western blot analyses confirmed the foregoing results (Figure 7). Altogether, Hbl B as well as L₂ and L₁ could be detected in the elution fraction of the Hbl B-specific 1B8-IAC and prove the pronounced complex formation between the single Hbl components in natural supernatants.

Table 2. Proportion of Hbl components L₂, L₁ and B in sample flow-through, wash and elution fraction after IAC purification of *B. cereus* MHI 1532 supernatant. Hbl B-specific mAb 1B8 [29] and Hbl L₂-specific mAb 1H9 (this study) were used for IAC. Hbl components were determined in sandwich EIAs: Hbl L₂: mAbs 1A12 [32]/1H9-HRP (this study); Hbl L₁: mAbs 1E9 [29]/1G8-HRP (this study); Hbl B: mAbs 1D12 (this study)/1B8-HRP [29]. NheB was also measured as a control (mAbs 2B11/1E11-HRP) [20]. EIA titres were multiplied with the respective sample volume resulting in units. The respective units determined in MHI 1532 supernatant were set to 100%.

Hbl B-Specific IAC (1B8)			
	Sample Flow-Through	Wash Fraction	Elution Fraction
Hbl L ₂	51%	20%	29%
Hbl L ₁	<5%	<5%	180%
Hbl B	<5%	<5%	187%
NheB	97%	-	3%
Hbl L ₂ -Specific IAC (1H9)			
	Sample Flow-Through	Wash Fraction	Elution Fraction
Hbl L ₂	9%	1%	90%
Hbl L ₁	55%	4.5%	2%
Hbl B	110%	10%	1%




Figure 7. Western blot analyses of Hbl B-specific IAC fractions of MHI 1532 supernatant: 1, supernatant of strain MHI 1532; 2, sample flow-through; 3, wash fraction; and 4, elution fraction. Toxin components were detected using the following mAbs: 1H9 (Hbl L₂), 1E9 (Hbl L₁), 1B8 (Hbl B), and 1E11 (NheB) ([20,33] and this study).

3. Discussion

With the construction of an *nheABC* deletion mutant and the establishment of a system for overexpression and purification of active recombinant Hbl components in *E. coli*, the first important steps towards clarification of the molecular mode-of-action of Hbl have been made. Earlier studies had been laborious and not fully conclusive, as the second three-component enterotoxin Nhe is

always present in crude *B. cereus* culture supernatants [28,29]. Furthermore, Hbl was purified in these early studies via anion exchange chromatography, including the possibility that the resulting preparations might have contained trace contaminations of Nhe [10,23,30]. As Nhe dominates toxicity studies, another approach to assess the peculiar Hbl activity was to remove NheB via subtractive immunoaffinity chromatography (IAC) and attribute the remaining toxic activity to Hbl [33]. By using rHbl components in the present study, no other *B. cereus* toxin is involved and the single Hbl components can be applied in defined concentrations and proportions. The three rHbl components produced in *E. coli* are functionally active and cytotoxic, but it must be admitted that cytotoxic activity is reduced compared to natural Hbl appearing in *B. cereus* culture supernatants (refer to Figure 1C,D).

Based on these reactive proteins and a broad range of Hbl-specific mAbs, complex formation between the single Hbl components could be detected for the first time. Via Dot blots, hybrid sandwich EIAs and immunoaffinity chromatography, Hbl L₁-B and Hbl L₁-L₂ complex formation could be shown both for the recombinant Hbl proteins as well as in natural *B. cereus* culture supernatants (refer to Figures 3, 4 and 6). Particularly, the L₁ and B components seem to be highly complexed. The only, comparably weak interaction between Hbl B and L₂ was observed in SPR measurements, when rHbl B was immobilized and high concentrations of rHbl L₂ were added (refer to Figure 5C). Apart from that, SPR measurements confirmed the results obtained in hybrid sandwich EIAs, indicating that there is an interaction and complex formation between Hbl L₁ and L₂ as well as L₁ and B. This Hbl complex formation also explains why all three Hbl components were detected in the elution fraction of Hbl B-specific IAC from strain MHI 1532 (Table 2 and Figure 7), which was initially used for immunogen preparation, and why mAbs specific for all three Hbl components (Table S1) were generated. Thus, it can be postulated that in natural *B. cereus* culture supernatants Hbl B is to a large extent bound in complexes. Further on, these complexes are characterized by K_D values of 4.7×10^{-7} M (L₁-B) and 3.4×10^{-6} M (B-L₂) (Figure 5). These are relatively low constants compared to the situation found for the NheB-C complexes, for which a value of 4.8×10^{-10} M was found [34]. This might be the reason why single Hbl components were obtained from *B. cereus* culture supernatants with the applied classical chromatographic approach in the early studies [23,30].

According to sequence homologies between the two three-component enterotoxin complexes of *B. cereus*, Hbl L₂ correlates with NheA, Hbl L₁ with NheB and Hbl B with NheC [31,35]. Thus, the Hbl L₁-B complexes found in this study would correspond to NheB-NheC complexes, which have already been well-described. It was shown that a defined level of NheB-NheC complexes as well as a sufficient amount of free NheB is necessary for efficient cell binding and toxicity [21,34]. Based on these data, a detailed model on the mode-of-action of Nhe could be developed [36]. Assuming that Hbl L₁ is equivalent to NheB and Hbl B to NheC, it can be speculated that the Hbl L₁-B complexes alone might be able to bind to the target cells and form a kind of “pro-pore” [34]. Analogously to NheA, Hbl L₂ would be the third component which, presumably after undergoing conformational changes, binds to the complex and completes the pore. However, the comparably low K_D values of the complexes found in this study, as well as the proposed binding order of the single components B-L₁-L₂ [19] oppose this theory.

Interestingly, in our study some of the newly generated mAbs against Hbl B enhanced Hbl toxicity towards Vero cells (refer to Figure 2A). By using purified rHbl B and flow cytometry analyses, an increased binding of Hbl B to Vero cells in the presence of the Hbl B-specific mAb 1D7 was found (Figure 2B and Table 1). Various studies describe enhancing effects of virus-specific mAbs, known as antibody-dependent-enhancement (ADE) [37,38]. ADE has been described for Dengue fever [39], HIV [40], Feline Infectious Peritonitis [41] and Ebola [42]. In 2004, ADE was first observed regarding the lethal toxin of *B. anthracis* [43]. The authors postulated stabilization of PA (protective antigen) binding to the cell surface via interaction of mAbs with macrophage Fcγ receptors. In contrast to this, involvement of Fc receptors can be excluded in our study, as they do not occur on the surface of Vero cells. Thus, the reason for the increased rHbl B binding remains unclear. One can speculate that through the two binding sites of the mAb, an antibody-mediated cross-linking of rHbl B is induced,

which might promote the binding of rHbl B to the cell surface. It is further possible that binding of the mAb results in a change of the tertiary structure of rHbl B enabling a better binding to the target cells.

Besides these toxicity-enhancing mAbs, also mAbs with neutralizing properties were also found. This is particularly true for the mAbs reactive with Hbl L₂ (refer to Table S1 and Figure 2A). However, these mAbs neutralize Hbl toxicity only by approximately 60%, in contrast to an earlier study, in which an NheB-specific mAb (1E11) was generated that neutralizes Nhe-dependent toxicity almost completely [20]. The partial neutralization of Hbl L₂-specific 1H9 and 1D8 indicates that both mAbs interact with regions of the toxin which are important, but not mandatory for toxic activity. Further studies are necessary to determine whether these mAbs hinder the proposed conformational change of the Hbl components during pore formation [26] or the putative attachment of Hbl L₂ to cell-bound Hbl B/L₁. It might also be possible that the mAbs are not able to access Hbl L₂, as it is partially bound in complexes with the other components, as shown in this study.

The demonstration of Hbl complex formation in the current study is a first step to characterize its mode-of-action in detail. Further studies are in progress to elucidate the epitope specificity of the mAbs to get new insights into the interaction of the single components. Cell culture studies will follow to investigate the impact of complex formation on the functionality and toxic activity of Hbl. Thus it can be elucidated if the complexes either support or hinder pore formation and if—next to Nhe—another example can be found for the so far unique, permeable “pro-pores”, or if Hbl conceals a different mechanism of hetero-oligomerization leading to pore formation.

4. Materials and Methods

4.1. Ethics Statement

Immunizations of mice for generating monoclonal antibodies were conducted in compliance with the German Law for Protection of Animals. Study permission was obtained by the Government of Upper Bavaria (permit number 55.2-1-54-2532.6-2-12).

4.2. Cell Lines and Culture Conditions

Vero cells were obtained from ECACC (European Collection of Cell Cultures) and cultured in 80 cm² culture flasks in a humidified incubator at 37 °C and 7% CO₂ in medium recommended by the supplier.

4.3. Bacterial Strains and Culture Conditions

In this study, the *B. cereus* strains F837/76 (DSM 4222), B4ac (DSM 4384), MHI 1532 (producing high amounts of Hbl toxin) and F837/76 Δ *nheABC* (producing Hbl, but no Nhe toxin) were used. For collection of toxin-rich supernatants, cells were grown in CGY medium with 1% glucose and treated as previously described [33]. Recombinant Hbl proteins were overexpressed in the *E. coli* strain BL21 (DE3), which was grown in LB medium containing 100 µg/mL ampicillin.

4.4. Construction of the *nheABC* Deletion Mutant

The *nheABC* deletion mutant was constructed as described previously with minor modifications [44]. Briefly, for the in-frame deletion of the *nheABC* gene cluster, an 808 bp upstream fragment of *bcf_09260* (*nheA*) and an 813 bp downstream fragment of *bcf_09270* (*nheC*) were amplified by PCR using the primer pairs *nheA*-BamHI/*nheA*-Spc (CGGGATCCCGAGTTACTGTTCGTTATACC; CGTTAGCGTTTAAAGTACATCCCCTGTAATTAAGTCTTTTTTCAC) and *nheC*-Spc/*nheC*-EcoRI (GCGTCCTCTTGTGAAATTAGAGGATTATACAGAAAATTACATGAAG; CGGAATTCCTCCATTATACGGTTCCTACTCG). To allow the selection of positive clones, the spectinomycin-resistance cassette from the TOPO/Spc plasmid was amplified with oligonucleotides For_Spc-K/Rev_Spc-K (GGATGTACTTAAACGCTAACG/CTCTAATTTACAAGAGGACGC) and inserted between upstream and downstream fragments using ligation-independent cloning (LIC) of PCR products [45].

Following the next PCR using the primer pair nheA-BamHI/nheC-EcoRI and the LIC construct as a template, the resulting fragment was cloned into the multiple cloning site of the conjugative suicide vector pAT113 via BamHI and EcoRI, giving rise to pAT113-Spc Δ nheABC. *E. coli* JM83/pRK24 was transformed with pAT113-Spc Δ nheABC and the resulting strain was used for transconjugal transfer into *B. cereus* F837/76. Conjugation was carried out as described [46]. Transconjugants were screened for spectinomycin resistance and erythromycin sensitivity. Gene cluster deletion and integration of the resistance cassette resulting from a double-crossover recombination event were confirmed by PCR and sequencing.

4.5. Cloning of Recombinant Hbl (rHbl) Components

The genes encoding Hbl L₂ (*hblC*; bcf_15295), Hbl L₁ (*hblD*; bcf_15290) and Hbl B (*hblA*; bcf_15285) were amplified using the primer pairs HblL₂-fw-KpnI (ATATGGTACCCCAAGCAGAAACTCAACAAGAAA) and HblL₂-rev-NcoI (ATATCCATGGTCAAAATTT ATACACTTGTCTTC), HblL₁-fw-SacII (ATATCCGCGGATGGCACAAGAAACGACCGCTCAAG) and HblL₁-rev-NcoI (ATATCCAATGGCCTCCTGTTTAAAAGCAATATC) and HblB-fw-KpnI (ATATGGTACCCGCAAGTGA AATTGAACAAACGAAC) and HblB-rev-NcoI (ATATCCATGGCTATTTTTGTGGAGTAACAGTT TCTAC), respectively. Chromosomal DNA from strain F837/76 was used as template. With the chosen primers, genes were amplified lacking the sequences for the N-terminal signal peptides for secretion [47,48]. *hblD* was cloned into pASK-IBA3plus (iba lifesciences), adding a C-terminal strep-tag to the recombinant Hbl L₁ protein. *hblC* and *hblA* were cloned into pASK-IBA5plus (iba lifesciences), resulting in addition of N-terminal strep-tags. Sequencing was performed using the primers pASK-IBA-seq-fw (CACTCCCTATCAGTGATAG) and pASK-IBA-seq-rev (GCACAATGTGCGCCAT).

4.6. Overexpression of rHbl Components

For overexpression of the rHbl components the *E. coli* strain BL21 (DE3) was used. Fifty millimetres LB medium with 100 μ g/mL ampicillin were inoculated to an OD₆₀₀ of 0.15. Cells were grown at 37 °C to an OD₆₀₀ of 0.8–0.9. After overexpression was induced by adding 1 μ g/mL doxycycline, cells were grown for further four hours and then harvested by centrifugation.

4.7. Purification of rHbl Components

The *E. coli* cell pellet was dissolved in 15 mL resuspension buffer (100 mM Tris, 500 mM NaCl, 1 mM EDTA, pH 8) containing protease inhibitor complete (Roche) and 100 μ g/mL lysozyme. Cells were subsequently disrupted in an ultrasonic bath for 2 \times 15 min on ice. Cell debris was removed by centrifugation for 30 min at 14,000 \times g and 4 °C. The remaining cell extract was filtered through a 0.2 μ m filter. All strep-tagged Hbl components were purified via a 0.5 mL Strep-Tactin[®]-Sephacel[®] matrix (iba lifesciences) in a Poly-Prep chromatography column (Biorad) according to the protocol provided by the supplier. Proteins were eluted in buffer containing 100 mM Tris, 500 mM NaCl, 1 mM EDTA and 2.5 mM D-desthiobiotin, pH 8. Protein concentrations were determined after SDS-PAGE by staining with Sypro Ruby in comparison to a BSA concentration standard.

4.8. Production of Monoclonal Antibodies (mAbs)

For the preparation of the immunogen, toxin was purified via immunoaffinity chromatography (IAC) from a total of 300 mL supernatant of *B. cereus* strain MHI 1532 grown in CGY medium. For this purpose, the previously established Hbl B-specific mAb 1B8 (10 mg) [29] was coupled to 1 g CNBr-activated sepharose 4B. The column was washed with 20 mL PBS before the toxin-containing culture supernatant was applied. After a washing step with 20 mL PBS, the toxin was eluted by addition of 16 mL glycine/HCl solution (pH 2.5). Subsequently, the eluate was neutralized with 1 M Tris (pH 7.0) and dialyzed three times overnight at 4 °C against PBS. Five 12-week-old female mice (BALB/c and BALB/c \times [NZW \times NZB]) were immunized with this preparation. Each mouse received 15 μ g purified toxin (immunization and first booster injection after 9 weeks) and another 12 μ g (second

booster injection after 15 weeks) emulsified in Sigma adjuvant. Three days before cell fusion each mouse received a final injection of 20 µg toxin diluted in 0.9% NaCl-solution. Cell fusion experiments, establishment of hybridomas, mass production and antibody purification were performed as described previously [20,32].

4.9. SDS-PAGE, Sypro Staining and Immunoblotting

SDS-PAGE analyses were carried out on a PhastGel gradient (10 to 15%) minigel system (GE Healthcare, Munich, Germany). For Sypro staining, proteins were fixed on the gel for 2 × 30 min in 50% MeOH and 7% acetic acid. The gel was then incubated with 2 mL Sypro Ruby protein stain overnight at room temperature. After 30 min washing in 10% MeOH and 7% acetic acid and additional washing for 10 min in H₂O, fluorescence signals were detected on a Kodak imager (Eastman Kodak Company, Rochester, NY, USA).

For immunoblotting, proteins were blotted to a PVDF-P membrane (Millipore, Billerica, MA, USA), blocked in 3% casein-PBS and incubated with 2 µg/mL mAbs 8B12 (Hbl L2) [32], 1E9 (Hbl L1) [29], 1B8 (Hbl B) [29], 1E11 or 2B11 (NheB) [20], 1A8 (NheA) [20], 3D6 (NheC) [21], mAb 1H9 (this study), or the strep-specific StrepMAB-Classic (iba lifesciences) for 1 h at room temperature. After 3 washing steps in PBS with 0.1% Tween 20, a 1:2000 dilution of rabbit anti-mouse-horseradish peroxidase conjugate (Dako) was used as secondary antibody. After three further washing steps in PBS with 0.1% Tween 20 and two in PBS, Super Signal Western Femto Maximum Sensitivity Substrate (Pierce) was applied. Chemiluminescence signals were detected on a Kodak imager (Eastman Kodak).

4.10. Labelling of mAbs

For use as detection antibodies in the sandwich EIAs, mAbs were coupled to activated peroxidase (HRP) according to the instructions of the manufacturer (Roche). The resulting conjugate was stabilized with 1% BSA and StabilZyme[®] HRP Conjugate Stabilizer (SurModics) and conserved with 0.01% Thimerosal.

For flow cytometric analyses, mAb 1G8 was labelled with Alexa Fluor[®] 488 (Thermo Scientific, Waltham, MA, USA). For that, 2 mg 1G8 (in 1 mL PBS) were mixed with 200 µL Alexa Fluor[®] 488. The mixture was stirred gently for 1 h at room temperature in the dark. To remove unbound Alexa dye, 10 mL PBS were added and the material was transferred to a Amicon[®] Ultra-4 centrifugal filter unit (Millipore) and centrifuged for 20 min (3000 rpm, 4 °C). The labelled mAb was washed with another 10 mL PBS by repeating the centrifugation step, and afterwards resuspended in PBS. NaN₃ (0.1%) was added for conservation and 1% BSA for stabilization.

4.11. Flow Cytometry

For flow cytometry analyses, Vero cells were adjusted to 1×10^6 cells in 1 mL EC buffer (140 mM NaCl, 15 mM HEPES, 1 mM MgCl₂, 1 mM CaCl₂, 10 mM glucose pH 7.2). Then 6.5 pmol/mL rHbl B and, if applicable, mAbs were added (ratio rHbl B:mAb = 1:1). The mixture was incubated for 1 h at 37 °C under moderate agitation. Then, 2 mL 1% BSA-PBS were added and cells were centrifuged for 5 min at 800 rpm. Cells were washed again in 2 mL 1% BSA-PBS. When rHbl B and mAb 1D7 were applied successively, the incubation step at 37 °C and the washing step were repeated. For detection of cell-bound rHbl B, the samples were incubated with 3 µg/mL Hbl B-specific Alexa Fluor[®] 488-labelled mAb 1G8 for 1 h at 4 °C. After additional washing, samples were resuspended in 500 µL 1% BSA-PBS and subsequently analysed in a FACS Calibur using the CellQuestPro software (BD Bioscience).

4.12. Enzyme Immunoassays (EIAs)

Indirect and sandwich enzyme immunoassays were performed as described before [20,28,32,49].

For detection of rHbl components, established mAbs were used (1A12 and 8B12 [32] for Hbl L₂, 1E9 [29] for Hbl L₁ and 1B8 [29] for Hbl B), as well as the ones newly generated in this study (Table S1). To determine relative affinities of the newly generated mAbs, *B. cereus* culture supernatants and rHbl

components were used in indirect EIAs. For that, dilution series of the antigens were applied, followed by the cell culture supernatants (constantly 1:20 in PBS). The relative affinity corresponds with the dilution that results in an absorbance value of 1.0. The productivity of the hybridoma cell lines was also determined in indirect EIAs. Supernatant of *B. cereus* MHI 1532 was applied (constantly 1:10 in PBS), followed by dilution series of the cell culture supernatants.

rHbl complex formation was investigated using indirect and sandwich EIAs. In the indirect assay, the microtiter plate was coated with a serial dilution of rHbl L₁ (120–0 pmol/mL) overnight. After washing, the second rHbl component was applied in constant concentration (60 pmol/mL) for 1 h. After blocking for 30 min with 3% sodium-caseinate in PBS, HblB-specific mAb 1B8 [29] and Hbl L₂-specific mAb 1H9 (this study) (2 µg/mL in PBS) were applied, respectively. After additional washing, rabbit-anti-mouse-HRP conjugate (1:2000 in 1% sodium-caseinate in PBS) was applied for detection. In the sandwich assay, the microtiter plate was coated with 10 µg/mL mAbs 1E9 [29] or 1G8 (this study), both Hbl L₁-specific, overnight. While the plate was blocked for 30 min with 3% sodium-caseinate in PBS, a mixture of rHbl components (L₁+B or L₁+L₂; 1.5 pmol/µL each, ratios 1:1, 5:1, 1:5, 10:1 or 1:10) was incubated at RT. The mixtures were applied to the microtiter plate as serial dilution from 75 to 0 pmol/mL. After washing, a specific mAb conjugate was applied for detection (1:2000 in 1% sodium-caseinate in PBS; 1B8-HRP [29] against Hbl B or 1H9-HRP (this study) against Hbl L₂). Analogously to the detection of the rHbl components, sandwich EIAs were used to detect Hbl complexes in the supernatant of *B. cereus* strain F837/76, which was applied to the microtiter plates as serial dilution. One-site-binding curves were applied to depict the absorption values compared to the sample dilutions.

4.13. Dot Blot

One hundred microlitres per dot of the first purified rHbl component, diluted in PBS, were applied to a PVDF membrane (Immobilon-P, Millipore, USA) as dilution series from 480 to 3.75 pmol. The membrane was removed from the dotting chamber and blocked with 3% sodium-caseinate-PBS overnight. Subsequently, the second purified rHbl component was applied (30 pmol in PBS) and overlaid on the dots for 1 h. The membrane was washed for 3 × 10 min in PBS containing 0.1% Tween 20. After that, Hbl-specific mAbs were applied (1B8 against Hbl B [29], 1H9 against Hbl L₂ (this study); 1E9 [29] and 1G8 (this study) against Hbl L₁; 3 µg/mL in 3% sodium-caseinate-PBS with 0.025% Tween 20) and overlaid on the dots for 1 h. The membrane was again washed for 3 × 10 min in PBS containing 0.1% Tween 20 before anti-mouse-IgG-alkaline-phosphatase-conjugate (Sigma) was applied (1:10.000 in 3% sodium-caseinate-PBS with 0.025% Tween 20) for 1 h. Again, the membrane was washed for 3 × 10 min in PBS containing 0.1% Tween 20 and for 2 × 10 min in PBS before signals were detected using NBT/BCIP solution (Roche).

4.14. Surface Plasmon Resonance (SPR)

Binding measurements were performed on a BIACORE 3000 instrument (Biacore Inc., Piscataway, NJ, USA). In a first experiment, rHbl L₁ was coupled and rHbl L₂ and B were used as ligands. For that, L₁ was diluted to a final concentration of 416 nM in 10 mM sodium acetate, pH 4.8, and chemically immobilized (amine coupling, 560 RU bound) onto a CM5 sensor chip (Biacore Inc.). The L₂ and B protein samples were diluted in running buffer (PBS, 1 mM DTT and 0.005% Tween 20) and injected over the sensor chip surface at 30 µL/min at 20 °C. The samples were injected onto the sensor chip from the lowest to the highest concentration with injection of 250 nM ligand in duplicate within each experiment. L₂ and B protein samples were measured three and four times, respectively.

For the second experiment, rHbl B was diluted to a final concentration of 350 nM in 10 mM sodium acetate, pH 4.0. 500 RU were coupled onto a CM5 sensor chip. rHbl L₂ was diluted in the same running buffer as above and injected over the sensor chip surface at 30 µL/min at 20 °C. The experiment was repeated four times. Background subtraction was done using an unmodified sensor chip surface. Data were analysed using BIAevaluation program (Biacore Inc.). For each measurement the equilibrium

dissociation constant (K_D) was calculated from steady-state measurement. The K_{DS} from three or four experiments (see above) were used to calculate mean values and standard deviations. Despite long injection times the measurement of $L_1 + B$ did not reach full binding saturation for lower protein concentrations. Therefore, the derived K_D value is likely to be slightly underestimated.

4.15. Cytotoxicity Assays

Stock solutions (1.5 pmol/ μ L) of the rHbl components were used for toxicity assays on Vero cells. They were pre-mixed in appropriate ratios and added in 1:40 dilutions to the cells. Propidium iodide (PI) influx tests were performed as described before [33,49]. WST-1 bioassays were carried out as previously described [20,32,49]. For neutralization assays, 10 μ g/well purified mAbs were applied constantly with a serial dilution (starting 1:20) of culture supernatant of *B. cereus* strain F837/76 Δ nheABC.

Supplementary Materials: The following are available online at www.mdpi.com/2072-6651/9/9/288/s1. **Table S1:** Characteristics of the established hybridoma cell lines and mAbs, **Table S2:** Statistics of the curves fitted to the EIA and SPR experiments, **Figure S1:** Detection of Hbl complex formation via Dot blot.

Acknowledgments: This work was supported by the Federal Ministry of Education and Research (BMBF) of Germany (Food supply and analysis LEVERA, funding code 13N12611).

Author Contributions: F.T. prepared immunogens, characterized mAbs and complexes and wrote parts of the manuscript. R.D. immunized mice, generated hybridoma cell lines and was involved in experimental setup and writing of the manuscript. K.S. generated the F837/76 Δ nheABC mutant. R.J. performed SPR measurements. D.N. and E.M. were involved in experimental setup and writing of the manuscript. N.J. cloned Hbl genes and purified the corresponding proteins, performed hybrid sandwich EIAs, characterized the complexes and wrote the manuscript.

Conflicts of Interest: The authors declare no conflict of interest. The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.

References

1. Stenfors Arnesen, L.P.; Fagerlund, A.; Granum, P.E. From soil to gut: *Bacillus cereus* and its food poisoning toxins. *FEMS Microbiol. Rev.* **2008**, *32*, 579–606. [[CrossRef](#)] [[PubMed](#)]
2. Andersson, A.; Ronner, U.; Granum, P.E. What problems does the food industry have with the spore-forming pathogens *Bacillus cereus* and *Clostridium perfringens*? *Int. J. Food Microbiol.* **1995**, *28*, 145–155. [[CrossRef](#)]
3. Ehling-Schulz, M.; Frenzel, E.; Gohar, M. Food-bacteria interplay: Pathometabolism of emetic *Bacillus cereus*. *Front. Microbiol.* **2015**, *6*, 704. [[CrossRef](#)] [[PubMed](#)]
4. Lund, T.; De Buyser, M.L.; Granum, P.E. A new cytotoxin from *Bacillus cereus* that may cause necrotic enteritis. *Mol. Microbiol.* **2000**, *38*, 254–261. [[CrossRef](#)] [[PubMed](#)]
5. Dierick, K.; Van Coillie, E.; Swiecicka, I.; Meyfroidt, G.; Devlieger, H.; Meulemans, A.; Hoedemaekers, G.; Fourie, L.; Heyndrickx, M.; Mahillon, J. Fatal family outbreak of *Bacillus cereus*-associated food poisoning. *J. Clin. Microbiol.* **2005**, *43*, 4277–42799. [[CrossRef](#)] [[PubMed](#)]
6. Naranjo, M.; Denayer, S.; Botteldoorn, N.; Delbrassinne, L.; Veys, J.; Waegenaere, J.; Sirtaine, N.; Driesen, R.B.; Sipido, K.R.; Mahillon, J.; et al. Sudden death of a young adult associated with *Bacillus cereus* food poisoning. *J. Clin. Microbiol.* **2011**, *49*, 4379–4381. [[CrossRef](#)] [[PubMed](#)]
7. Agata, N.; Ohta, M.; Mori, M.; Isobe, M.A. A novel dodecadeptide, cereulide, is an emetic toxin of *Bacillus cereus*. *FEMS Microbiol. Lett.* **1995**, *129*, 17–20. [[CrossRef](#)] [[PubMed](#)]
8. Ehling-Schulz, M.; Fricker, M.; Scherer, S. *Bacillus cereus*, the causative agent of an emetic type of food-borne illness. *Mol. Nutr. Food Res.* **2004**, *48*, 479–487. [[CrossRef](#)] [[PubMed](#)]
9. Clavel, T.; Carlin, F.; Lairon, D.; Nguyen-The, C.; Schmitt, P. Survival of *Bacillus cereus* spores and vegetative cells in acid media simulating human stomach. *J. Appl. Microbiol.* **2004**, *97*, 214–219. [[CrossRef](#)] [[PubMed](#)]
10. Beecher, D.J.; Schoeni, J.L.; Wong, A.C. Enterotoxic activity of hemolysin BL from *Bacillus cereus*. *Infect. Immun.* **1995**, *63*, 4423–4428. [[PubMed](#)]
11. Lund, T.; Granum, P.E. Characterisation of a non-haemolytic enterotoxin complex from *Bacillus cereus* isolated after a foodborne outbreak. *FEMS Microbiol. Lett.* **1996**, *141*, 151–156. [[CrossRef](#)] [[PubMed](#)]

12. Hardy, S.P.; Lund, T.; Granum, P.E. CytK toxin of *Bacillus cereus* forms pores in planar lipid bilayers and is cytotoxic to intestinal epithelia. *FEMS Microbiol. Lett.* **2001**, *197*, 47–51. [[CrossRef](#)] [[PubMed](#)]
13. Fagerlund, A.; Ween, O.; Lund, T.; Hardy, S.P.; Granum, P.E. Genetic and functional analysis of the *cytK* family of genes in *Bacillus cereus*. *Microbiology* **2004**, *150*, 2689–2697. [[CrossRef](#)] [[PubMed](#)]
14. Guinebretiére, M.H.; Auger, S.; Galleron, N.; Contzen, M.; De Sarrau, B.; De Buyser, M.L.; Lamberet, G.; Fagerlund, A.; Granum, P.E.; Lereclus, D.; et al. *Bacillus cytotoxicus* sp. nov. is a novel thermotolerant species of the *Bacillus cereus* Group occasionally associated with food poisoning. *Int. J. Syst. Evol. Microbiol.* **2013**, *63*, 31–40. [[CrossRef](#)] [[PubMed](#)]
15. Lindbäck, T.; Fagerlund, A.; Rødland, M.S.; Granum, P.E. Characterization of the *Bacillus cereus* Nhe enterotoxin. *Microbiology* **2004**, *150*, 3959–3967. [[CrossRef](#)] [[PubMed](#)]
16. Fagerlund, A.; Lindbäck, T.; Storset, A.K.; Granum, P.E.; Hardy, S.P. *Bacillus cereus* Nhe is a pore-forming toxin with structural and functional properties similar to the ClyA (HlyE, SheA) family of haemolysins, able to induce osmotic lysis in epithelia. *Microbiology* **2008**, *154*, 693–704. [[CrossRef](#)] [[PubMed](#)]
17. Lindbäck, T.; Hardy, S.P.; Dietrich, R.; Sødning, M.; Didier, A.; Moravek, M.; Fagerlund, A.; Bock, S.; Nielsen, C.; Casteel, M.; et al. Cytotoxicity of the *Bacillus cereus* Nhe enterotoxin requires specific binding order of its three exoprotein components. *Infect. Immun.* **2010**, *78*, 3813–3821. [[CrossRef](#)] [[PubMed](#)]
18. Didier, A.; Dietrich, R.; Gruber, S.; Bock, S.; Moravek, M.; Nakamura, T.; Lindbäck, T.; Granum, P.E.; Märklbauer, E. Monoclonal antibodies neutralize *Bacillus cereus* Nhe enterotoxin by inhibiting ordered binding of its three exoprotein components. *Infect. Immun.* **2012**, *80*, 832–838. [[CrossRef](#)] [[PubMed](#)]
19. Sastalla, I.; Fattah, R.; Coppage, N.; Nandy, P.; Crown, D.; Pomerantsev, A.P.; Leppä, S.H. The *Bacillus cereus* Hbl and Nhe tripartite enterotoxin components assemble sequentially on the surface of target cells and are not interchangeable. *PLoS ONE* **2013**, *8*, e76955. [[CrossRef](#)] [[PubMed](#)]
20. Dietrich, R.; Moravek, M.; Bürk, C.; Granum, P.E.; Märklbauer, E. Production and characterization of antibodies against each of the three subunits of the *Bacillus cereus* nonhemolytic enterotoxin complex. *Appl. Environ. Microbiol.* **2005**, *71*, 8214–8220. [[CrossRef](#)] [[PubMed](#)]
21. Heilkenbrinker, U.; Dietrich, R.; Didier, A.; Zhu, K.; Lindbäck, T.; Granum, P.E.; Märklbauer, E. Complex formation between NheB and NheC is necessary to induce cytotoxic activity by the three-component *Bacillus cereus* Nhe enterotoxin. *PLoS ONE* **2013**, *8*, e63104. [[CrossRef](#)] [[PubMed](#)]
22. Beecher, D.J.; MacMillan, J.D. A novel bicomponent hemolysin from *Bacillus cereus*. *Infect. Immun.* **1990**, *58*, 2220–2227. [[PubMed](#)]
23. Beecher, D.J.; Macmillan, J.D. Characterization of the components of hemolysin BL from *Bacillus cereus*. *Infect. Immun.* **1991**, *59*, 1778–1784. [[PubMed](#)]
24. Beecher, D.J.; Wong, A.C. Tripartite hemolysin BL from *Bacillus cereus*. Hemolytic analysis of component interactions and a model for its characteristic paradoxical zone phenomenon. *J. Biol. Chem.* **1997**, *272*, 233–239. [[CrossRef](#)] [[PubMed](#)]
25. Beecher, D.J.; Wong, A.C. Tripartite haemolysin BL: Isolation and characterization of two distinct homologous sets of components from a single *Bacillus cereus* isolate. *Microbiology* **2000**, *146*, 1371–1380. [[CrossRef](#)] [[PubMed](#)]
26. Madegowda, M.; Eswaramoorthy, S.; Burley, S.K.; Swaminathan, S. X-ray crystal structure of the B component of Hemolysin BL from *Bacillus cereus*. *Proteins* **2008**, *71*, 534–540. [[CrossRef](#)] [[PubMed](#)]
27. Guinebretiére, M.H.; Broussolle, V.; Nguyen-The, C. Enterotoxigenic profiles of food-poisoning and food-borne *Bacillus cereus* strains. *J. Clin. Microbiol.* **2002**, *40*, 3053–3056. [[CrossRef](#)] [[PubMed](#)]
28. Moravek, M.; Dietrich, R.; Bürk, C.; Broussolle, V.; Guinebretiére, M.H.; Granum, P.E.; Nguyen-The, C.; Märklbauer, E. Determination of the toxic potential of *Bacillus cereus* isolates by quantitative enterotoxin analyses. *FEMS Microbiol. Lett.* **2006**, *257*, 293–298. [[CrossRef](#)] [[PubMed](#)]
29. Wehrle, E.; Moravek, M.; Dietrich, R.; Bürk, C.; Didier, A.; Märklbauer, E. Comparison of multiplex PCR, enzyme immunoassay and cell culture methods for the detection of enterotoxinogenic *Bacillus cereus*. *J. Microbiol. Methods* **2009**, *78*, 265–270. [[CrossRef](#)] [[PubMed](#)]
30. Beecher, D.J.; Wong, A.C. Improved purification and characterization of hemolysin BL, a hemolytic dermonecrotic vascular permeability factor from *Bacillus cereus*. *Infect. Immun.* **1994**, *62*, 980–986. [[PubMed](#)]
31. Ryan, P.A.; Macmillan, J.D.; Zilinskas, B.A. Molecular cloning and characterization of the genes encoding the L1 and L2 components of hemolysin BL from *Bacillus cereus*. *J. Bacteriol.* **1997**, *179*, 2551–2556. [[CrossRef](#)] [[PubMed](#)]

32. Dietrich, R.; Fella, C.; Strich, S.; Märtlbauer, E. Production and characterization of monoclonal antibodies against the hemolysin BL enterotoxin complex produced by *Bacillus cereus*. *Appl. Environ. Microbiol.* **1999**, *65*, 4470–4474. [[PubMed](#)]
33. Jessberger, N.; Dietrich, R.; Bock, S.; Didier, A.; Märtlbauer, E. *Bacillus cereus* enterotoxins act as major virulence factors and exhibit distinct cytotoxicity to different human cell lines. *Toxicon* **2014**, *77*, 49–57. [[CrossRef](#)] [[PubMed](#)]
34. Zhu, K.; Didier, A.; Dietrich, R.; Heilkenbrinker, U.; Waltenberger, E.; Jessberger, N.; Märtlbauer, E.; Benz, R. Formation of small transmembrane pores: An intermediate stage on the way to *Bacillus cereus* non-hemolytic enterotoxin (Nhe) full pores in the absence of NheA. *Biochem. Biophys. Res. Commun.* **2016**, *469*, 613–618. [[CrossRef](#)] [[PubMed](#)]
35. Granum, P.E.; O'Sullivan, K.; Lund, T. The sequence of the non-haemolytic enterotoxin operon from *Bacillus cereus*. *FEMS Microbiol. Lett.* **1999**, *177*, 225–229. [[CrossRef](#)] [[PubMed](#)]
36. Didier, A.; Dietrich, R.; Märtlbauer, E. Antibody Binding Studies Reveal Conformational Flexibility of the *Bacillus cereus* Non-Hemolytic Enterotoxin (Nhe) A-Component. *PLoS ONE* **2016**, *11*, e0165135. [[CrossRef](#)] [[PubMed](#)]
37. Tirado, S.M.; Yoon, K.J. Antibody-dependent enhancement of virus infection and disease. *Viral Immunol.* **2003**, *16*, 69–86. [[CrossRef](#)] [[PubMed](#)]
38. Takada, A.; Kawaoka, Y. Antibody-dependent enhancement of viral infection: Molecular mechanisms and in vivo implications. *Rev. Med. Virol.* **2003**, *13*, 387–398. [[CrossRef](#)] [[PubMed](#)]
39. Guzman, M.G.; Alvarez, M.; Halstead, S.B. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: An historical perspective and role of antibody-dependent enhancement of infection. *Arch. Virol.* **2013**, *158*, 1445–1459. [[CrossRef](#)] [[PubMed](#)]
40. Willey, S.; Aasa-Chapman, M.; O'Farrell, S.; Pellegrino, P.; Williams, I.; Weiss, R.A.; Neil, S.J.D. Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection. *Retrovirology* **2011**, *8*, 16. [[CrossRef](#)] [[PubMed](#)]
41. Takano, T.; Kawakami, C.; Yamada, S.; Satoh, R.; Hohdatsu, T. Antibody-dependent enhancement occurs upon re-infection with the identical serotype virus in feline infectious peritonitis virus infection. *J. Vet. Med. Sci.* **2008**, *70*, 1315–1321. [[CrossRef](#)] [[PubMed](#)]
42. Takada, A.; Feldmann, H.; Ksiazek, T.G.; Kawaoka, Y. Antibody-dependent enhancement of Ebola virus infection. *J. Virol.* **2003**, *77*, 7539–7544. [[CrossRef](#)] [[PubMed](#)]
43. Mohamed, N.; Li, J.; Ferreira, C.S.; Little, S.F.; Friedlander, A.M.; Spitalny, G.L.; Casey, L.S. Enhancement of anthrax lethal toxin cytotoxicity: A subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages. *Infect. Immun.* **2004**, *72*, 3276–3283. [[CrossRef](#)] [[PubMed](#)]
44. Lücking, G.; Dommel, M.K.; Scherer, S.; Fouet, A.; Ehling-Schulz, M. Cereulide synthesis in emetic *Bacillus cereus* is controlled by the transition state regulator AbrB, but not by the virulence regulator PlcR. *Microbiology* **2009**, *155*, 922–931. [[CrossRef](#)] [[PubMed](#)]
45. Aslanidis, C.; de Jong, P.J. Ligation-independent cloning of PCR products (LIC-PCR). *Nucleic Acids Res.* **1990**, *18*, 6069–6074. [[CrossRef](#)] [[PubMed](#)]
46. Pezard, C.; Berche, P.; Mock, M. Contribution of individual toxin components to virulence of *Bacillus anthracis*. *Infect. Immun.* **1991**, *59*, 3472–3477. [[PubMed](#)]
47. Fagerlund, A.; Lindbäck, T.; Granum, P.E. *Bacillus cereus* cytotoxins Hbl, Nhe and CytK are secreted via the Sec translocation pathway. *BMC Microbiol.* **2010**, *10*, 304. [[CrossRef](#)] [[PubMed](#)]
48. Økstad, O.A.; Gominet, M.; Purnelle, B.; Rose, M.; Lereclus, D.; Kolstø, A.B. Sequence analysis of three *Bacillus cereus* loci carrying PlcR-regulated genes encoding degradative enzymes and enterotoxin. *Microbiology* **1999**, *145*, 3129–3138. [[CrossRef](#)] [[PubMed](#)]
49. Jessberger, N.; Rademacher, C.; Krey, V.M.; Dietrich, R.; Mohr, A.K.; Böhm, M.E.; Scherer, S.; Ehling-Schulz, M.; Märtlbauer, E. Simulating Intestinal Growth Conditions Enhances Toxin Production of Enteropathogenic *Bacillus cereus*. *Front. Microbiol.* **2017**, *8*, 627. [[CrossRef](#)] [[PubMed](#)]

